The Pitfalls Of Obesity Treatment
While scoring high on Total Body Weight Loss (TBWL%), gold-standard bariatric treatments are avoided by most patients and insurers, as these treatments are highly-invasive, may lead to significant adverse events, and often involve irreversible GI tract reconfigurations. In consequence, they are performed in less than 1% of the eligible population.
Alternatives such as intra-gastric balloons, while utilizing safer trans-oral access and being covered for lower-BMI patients, are temporary and achieve lower TBWL%. Endoscopic gastroplasty, which does provide much higher TBWL%, is an extremely cumbersome procedure that is generally inaccessible to patients and physicians alike.
endozip™
An Automated Stitch In Time
endozip™ is a fully automated, operator–independent, minimally-invasive suturing system that enables to create durable restrictive sutures in the GI space.
Shape & Zip. It’s As Simple As That.
Introduce
Trans-oral endoscopic access and positioning directly in the designated area of restriction
Shape
Accurate grasping and stitching of the stomach tissue from within
Zip
Helical needle is activated automatically to connect anterior and posterior walls, securing the suture under direct vision
Remove
Smooth system removal
Simple, Reproducible Procedures
Making safe and effective endoscopic weight-loss treatments accessible to both patients and their physicians.
Consistent Suture Size And Depth
High Suture
Density
Internal
Suturing
Durable, Longer Lasting Restrictive Sutures
Operator
Independence
Reproducible
Procedures
Ease Of Use &
Short Learning Curve
Suitable For Gastroenterologists & Bariatric Surgeons
Clinical Status
Nitinotes has recently completed its FIH study in Spain. Led by Dr. Lopez Nava,
Director of the Bariatric Endoscopy Unit at HM Sanchinarro University Hospital, Madrid.
About Nitinotes
Nitinotes is a privately-held medical device company based in Tel Aviv. Its flagship product is the endozip™, a novel gastroscopic solution for safer, simpler GI suturing. Backed by preclinical success and prominent KOLs, Nitinotes’s gastric volume restriction provides an effective, minimally-invasive solution to class 1 and 2 obesity patients, for the majority of whom gold-standard bariatric surgery is uncovered and/or inadvisable.
In a series of animal studies and ex-vivo tests on fresh human tissue remains from sleeve gastrectomy, endozip™ has shown promising results, with a reproducible technique. Recently, Nitinotes has successfully performed a FIH study in Spain, led by Dr. Lopez Nava, director of bariatric endoscopy at HM Sanchinarro University Hospital, Madrid.
Nitinotes is headed by a team of R&D
and business experts, including:
Raz Bar-On
BSc, MBA
CEO
Irit Yaniv
MD, MBA
Executive Chairperson
Asaf Asherov
BSc
VP R&D
Hagit Ephrath
MA
VP QA, Regulatory and Medical Affairs
Actively Supported by
